华领医药绩后涨超4%年度毛利同比增超2.3倍预期华堂宁®入保后销售额大幅上升

动脉网
28 Mar

华领医药-B(02552)发布截至2024年12月31日的年度业绩,收入同比增长234.02%至2.56亿元人民币,毛利同比增加233.72%至1.25亿元。公司核心产品华堂宁®销售额大幅增长,2024年度售出约210.5万盒,销售额达2.56亿元,较2023年的7660万元显著提升。华堂宁®于2023年底被纳入国家医保药品目录,预计未来几年销售额将持续上升。2024年是华堂宁®纳入医保后的首个...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10